Table 1:

Demographics and treatment characteristics (N = 173)

No. (%)Mean (SD)Median (IQR)
Demographics
    Sex
        Male89 (51)
        Female84 (49)
    Race/ethnicity
        White124 (72)
        Asian3 (2)
        Black21 (12)
        Hispanic18 (10)
        Others7 (4)
    Current age (yr)14.4 (4.6)13.5 (10.7–17.6)
    Patient's highest education (yr)7.7 (3.9)7.0 (4.0–11.0)
    Maternal education (yr)13.6 (2.5)13.0 (12.0–16.0)
    Paternal education (yr)13.6 (3.1)12.0 (12.0–16.0)
Treatment characteristics
    Age at diagnosis (yr)6.7 (4.3)5.3 (3.5–8.6)
    Time since diagnosis (yr)7.7 (1.8)7.5 (6.3–9.1)
Treatment risk stratum
        Low102 (59)
        Standard71 (41)
Chemotherapy dosesa
    Oral dexamethasone (mg/m2)1096.4 (303.2)1099.9 (985.3–1246.1)
    IV high-dose cytarabine (g/m2)8.5 (3.5)8.0 (8.0–8.0)
    IV leucovorin (mg/m2)343.5 (207.1)300.0 (220.0–390.0)
    IV high-dose methotrexateb (g/m2)15.4 (6.7)14.2 (11.4–19.0)
    IT MHA (No. of counts)14.4 (4.0)13.0 (12.0–16.0)

  • Note:—IQR indicates interquartile range; IT MHA, intrathecal injection of methotrexate plus hydrocortisone plus cytarabine.

  • ↵a Except for IT MHA, all drug doses are presented as cumulative doses (g/m2 or mg/m2).

  • ↵b High-dose IV methotrexate was defined as a daily dose of >1 g/m2 of IV methotrexate.